In a major step toward making healthcare more affordable, the National Pharmaceutical Pricing Authority (NPPA) has announced a reduction in the retail prices of 35 essential medicines widely used for chronic and acute conditions. The revised prices, notified by the Ministry of Chemicals and Fertilisers, cover drugs used for cardiac care, diabetes, infections, inflammation, and psychiatric illnesses.
The move is aimed at providing relief to millions of patients, especially those requiring long-term medication. The NPPA’s latest price control order includes medications manufactured and marketed by some of India’s leading pharmaceutical companies.
🔹 Key Drug Formulations Affected:
Among the most prominent formulations affected by this price cut are:
- Aceclofenac + Paracetamol + Trypsin Chymotrypsin (anti-inflammatory)
- Amoxycillin + Potassium Clavulanate (antibiotic)
- Atorvastatin + Clopidogrel (cardiovascular)
- Empagliflozin + Metformin, Sitagliptin + Metformin (anti-diabetic)
- Cefixime + Paracetamol oral suspensions (paediatric use)
- Cholecalciferol drops (Vitamin D)
- Diclofenac injection (pain relief)
The revised prices include:
- Rs 13.00 per tablet for Aceclofenac-Paracetamol-Trypsin Chymotrypsin (Akums/Dr Reddy’s)
- Rs 15.01 for the same combination marketed by Cadila Pharmaceuticals
- Rs 25.61 per tablet for Atorvastatin 40 mg + Clopidogrel 75 mg
- Rs 31.77 per ml for Diclofenac Injection
The NPPA clarified that all notified prices are exclusive of GST, which may be added separately where applicable.
🔹 Implementation and Compliance:
The official order mandates that:
- Retailers and dealers must display the revised price list prominently at their premises.
- Manufacturers must update price lists (Form V) via the Integrated Pharmaceutical Database Management System (IPDMS) and send them to the NPPA and respective state drug controllers.
- Non-compliance may invite action under the Drugs (Prices Control) Order, 2013 and the Essential Commodities Act, 1955, including recovery of overcharged amounts with interest.
🔹 Regulatory Oversight:
The NPPA, which operates under the Ministry of Chemicals and Fertilisers, is India’s primary drug price regulator. It is responsible for fixing and revising the prices of both scheduled (price-controlled) and non-scheduled (marketed) drugs, ensuring accessibility without compromising quality or availability.
This new directive supersedes all previous price notifications related to the specified formulations and manufacturers, ensuring uniformity and transparency in medicine pricing.
🔹 Impact:
Healthcare experts have welcomed the move, calling it a pro-patient measure that could reduce the financial burden on households, particularly those managing lifestyle diseases like diabetes and heart conditions. The inclusion of paediatric and essential vitamin formulations further reflects the government’s focus on inclusive healthcare.
Patients are advised to check updated pricing at pharmacies and report any overcharging to authorities.
Click Here To Follow Our WhatsApp Channel
You Might Also Like:
Dr. Shaheena Akhtar Becomes First Female PhD in Persian
Why Strengthening BRICS Better Serves India’s Future Than Leaning Towards the United States
Lalla Ded Hospital Video Sparks Probe After Doctor Films Inside OT; Health Dept Orders 24-Hour Inquiry